Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Escaping from the TGFbeta anti-proliferative control.

Joan Seoane1

  • 1Institució Catalana de Recerca i Estudis Avançats (ICREA), Medical Oncology Program Vall d'Hebron University Hospital Research Institute, Barcelona, Spain. jseoane@ivr.vhebron.net

Carcinogenesis
|May 16, 2006
PubMed
Summary

Transforming growth factor-beta (TGFbeta) normally suppresses tumors by inhibiting cell growth. Cancer cells develop ways to block TGFbeta signaling, allowing tumors to grow and potentially making TGFbeta an oncogenic factor.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression.

Nature communications·2026
Same author

Publisher Correction: Polyamine-dependent metabolic shielding regulates alternative splicing.

Nature·2026
Same author

Polyamine-dependent metabolic shielding regulates alternative splicing.

Nature·2026
Same author

Development and Preclinical Evaluation of a Zirconium-89-Labeled Immunoconjugate for Positron Emission Tomography Imaging of Leukemia Inhibitory Factor in Glioblastoma.

ACS pharmacology & translational science·2025
Same author

Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium.

Neuro-oncology·2025
Same author

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.

Cancer research·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Transforming growth factor-beta (TGFbeta) is vital for tissue balance and acts as a tumor suppressor by inhibiting epithelial cell proliferation.
  • Disruption of the TGFbeta pathway is linked to numerous human diseases, particularly cancer.

Purpose of the Study:

  • To review the molecular mechanisms underlying the loss of TGFbeta's tumor-suppressive function in cancer.
  • To provide insights into how cancer cells evade TGFbeta's anti-proliferative effects.

Main Methods:

  • This review synthesizes recent research findings.
  • Analysis of molecular mechanisms of TGFbeta pathway disruption in cancer.

Main Results:

  • Cancer cells evade TGFbeta's tumor-suppressive effects through somatic mutations or by blocking cytostatic responses.

Related Experiment Videos

  • During tumor progression, TGFbeta can transition from a tumor suppressor to an oncogenic factor.

    • Conclusions:

    • Understanding the mechanisms of TGFbeta pathway disruption is crucial for developing targeted cancer therapies.
    • Identifying how TGFbeta signaling is impaired can guide the design of effective therapeutic strategies against cancer.